期刊文献+

依那普利联合胺碘酮治疗高血压合并阵发性心房纤颤临床观察

下载PDF
导出
摘要 目的探讨高血压合并阵发性心房纤颤的有效治疗途径。方法 96例患者随机分为观察组48例,对照组48例,观察组采用依那普利联合胺碘酮,对照组采用非洛地平联合胺碘酮。治疗1,6,12个月后对2组患者的血压水平、窦性心律维持率及左心房内径的变化进行比较。结果 2组患者在治疗后1,6,12个月血压均较治疗前明显下降,2组比较差异无统计学意义(P>0.05)。2组治疗后1个月窦性心律维持率及左房内径比较差异无统计学意义(P>0.05)。治疗后6,12个月窦性心律维持率及左房内径缩小观察组明显高于对照组(P<0.05)。结论依那普利联合胺碘酮是高血压合并阵发性心房纤颤的理想治疗药物。
作者 张春梅
机构地区 阳城县人民医院
出处 《基层医学论坛》 2011年第S1期34-35,共2页 The Medical Forum
  • 相关文献

参考文献3

二级参考文献27

  • 1Society of Cardiology, Chinese Medical Association.Retrospective investigation of hospitalized patients with atrial fibrillation in China's Mainland[J].Chinese Medical Journal,2004,17(12):1763-1767. 被引量:23
  • 2金玉华,方宁远,陆惠华,孟超.老年高血压病患者心脏结构改变与心律失常的关系[J].上海第二医科大学学报,2004,24(B11):49-52. 被引量:27
  • 3Swedberg K, Pfeffer MA, Cohen-solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from CHARM [ abstract] [ J]. J Am Coll Cardiol,2004,43:222A.
  • 4Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure:results from valsartan heart failure trial(Val-HeFT) [ J]. Am Heart J,2005,149:548-557.
  • 5Madrid AH, Peng J,Zamora J, et al. The role of angiotensin receptor blocks and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular disease:meta-analysis of randomized controlled clinical trials[J]. Pacing Clin Electrophysiol,2004,27(10) :1405- 1410.
  • 6Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers : a meta-analysis [ J ]. J Am Coll C ardiol, 2005,45 ( 11 ) : 1832-1849.
  • 7Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation [J]. J Clin Pharmacol,2006,46 (1):21-28.
  • 8Disertori M, Latini R, Maggioni AP,et al. Rationable and design of GISSI-atrial fibrillation trial : a randomized, prospective, muhicentre study on the use of valsartan,an angiotensin Ⅱ. AT1-receptor blocker,in the prevention of atrial fibrillation recurrence[ J]. J Cardiovasc Med ( Hargerstown), 2006,7 ( 1 ) : 29- 38.
  • 9Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of a large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients:the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease ( ONTARGET/TRANSCEND)triaI[ J]. Am Heart J,2004,148:52--61.
  • 10Tamargo J, Caballero R, Delpon E. Pharmacological approaches in the treatment of artrial fibrillation[J]. Curr Med Chem,2004,11 ( 1 ) :13-28.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部